Loading…
← CockpitCompetitor Analysis › ADRX ADARx Pharmaceuticals, Inc.Open in the cockpit ↗

ADARx Pharmaceuticals, Inc.ADRXCompetitor analysis, valuation and peers

United States · USD·Industrials›Biotechnology
Mkt cap
$1.43B
US dollars, full cap
Free float
41%
of shares outstanding
$/day
$6.73M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 20.0%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$12.82
1D-7.2%
1W-3.6%
1M-27.5%
3Mn/a
6Mn/a
YTDn/a
1Yn/a
ATR %14.5%
52w lowhigh44.8% off high

What ADARx Pharmaceuticals does

No business profile yet.

ADARx Pharmaceuticals at a glance

Size ADARx Pharmaceuticals (ADRX) is a United States Industrials company (Biotechnology) with a market value of $1.43B, the 1999th largest of 3,085 United States companies the cockpit tracks. Shares closed at $12.82 on 18 Nov 2026.

Growth The operating margin is -2,562.1% (peer median 6.9%).

Valuation It trades at 153.9× enterprise value to sales against a peer median of 1.7× (2nd most expensive of 20).

Short interest Short interest is 1.6% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

ADARx Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024
Revenuen/a$3.45M$0
Revenue growth———
Gross profitn/a$1.12M-$1.50M
EBITDAn/a-$86.0M-$56.7M
Net incomen/a-$73.1M-$46.4M
Free cash flown/a$259M-$49.0M
Capital expendituren/a$2.94M$455,000
Total debt$6.46M$7.74M$4.33M

Quarterly statements and history in the cockpit →

ADARx Pharmaceuticals competitors and peer comparison

How ADARx Pharmaceuticals compares with its peers

Peer set: Sector in the same market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

ADARx Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureADRXPeer medianRank in peer set
1-month return-27.5%-8.8%4th lowest of 21
Distance from 52-week high-44.8%-38.1%7th lowest of 21
Operating margin-2,562.1%6.9%2nd lowest of 20
EV / Sales153.9×1.7×2nd most expensive of 20
Growth the price implies (Req g, 7 yrs)-16.9%8.5%least demanding of 15

Peer table

Peer set: Sector in the same market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
ADARx Pharmaceuticals ADRXUnited States$1.43Bn/an/a-2,562%153.9×-16.9%n/a
MillerKnoll MLKNUnited States$1.43B+38%+1%6%0.8×7.3%+9.3%
Hub HUBGUnited States$1.44B-42%n/an/an/an/an/a
ICF International ICFIUnited States$1.40B+14%-5%8%1.0×-2.5%+4.4%
Helios Technologies HLIOUnited States$1.47B-43%+12%13%1.9×9.8%+9.9%
Clarivate CLVTUnited States$1.38B-12%-9%8%2.3×13.2%+14.4%
Global Ship Lease GSLUnited States$1.47B-1%+4%48%2.0×-13.7%+22.1%
Cimpress CMPRUnited States$1.37B-43%+10%6%0.8×5.6%+7.7%
Cadre CDREUnited States$1.37B+9%+18%12%2.3×15.3%+8.6%
Preformed Line Products PLPCUnited States$1.36B-17%+16%10%1.7×11.8%+7.5%
CRA International CRAIUnited States$1.35B+46%+13%10%1.9×6.6%+8.1%
JetBlue Airways JBLUUnited States$1.35B-25%+10%-6%0.9×n/an/a
Costamare CMREUnited States$1.53B-28%-42%44%3.3×-6.6%+13.0%
Hillman Solutions HLMNUnited States$1.53B+9%+6%6%1.6×17.5%+2.6%
Allient ALNTUnited States$1.32B+23%+13%10%2.5×24.9%+8.6%
Tennant TNCUnited States$1.30B-8%0%4%1.3×n/an/a
Alamo ALGUnited States$1.60B-14%+2%7%1.0×7.2%+6.6%
NuScale Power SMRUnited States$1.61B-62%-96%-9,493%229.2×n/an/a
ERock EROCUnited States$1.61Bn/a+43%-19%7.2×15.0%+42.5%
Werner Enterprises WERNUnited States$1.62B-32%+15%2%0.8×n/an/a
Distribution Solutions DSGRUnited States$1.62B+29%+7%4%1.1×n/an/a

Questions

Which companies are ADARx Pharmaceuticals's closest peers?
The cockpit's peer set: MillerKnoll (MLKN), Hub (HUBG), ICF International (ICFI), Helios Technologies (HLIO), Clarivate (CLVT), Global Ship Lease (GSL), Cimpress (CMPR), Cadre (CDRE).
Is ADARx Pharmaceuticals expensive compared with its peers?
On ev / sales it trades at 153.9× against a peer median of 1.7×, 2nd most expensive of 20 in its peer set.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.